Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2007 Jul;48(7):696-700. Korean.
    Published online Jul 31, 2007.
    https://doi.org/10.4111/kju.2007.48.7.696
    Copyright © 2007 The Korean Urological Association
    Original Article

    The Meaning of Metabolic Syndrome X in Patients Suffering with Benign Prostatic Hyperplasia

    Jeong Seon Park and Jong Kwan Park
      • Department of Urology, Chonbuk National University Medical School, Jeonju, Korea.
    • Corresponding author (Email: rain@chonbuk.ac.kr )
    Received April 05, 2007; Accepted June 04, 2007.

    Abstract

    Purpose

    We wanted to evaluate if metabolic syndrome X affects voiding symptoms and erectile function in those patients suffering with benign prostatic hyperplasia (BPH).

    Materials and Methods

    Between January 2003 and May 2006, we analyzed 68 patients suffering with both BPH and metabolic syndrome X and 112 patients suffering with BPH, but not metabolic syndrome as controls. The diagnosis of metabolic syndrome was made according to the recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel. The blood pressure, obesity, maximal flow rate, residual volume, International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIEF) were all measured. The biochemical analyses included determining the levels of serum glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and prostate-specific antigen (PSA). The total prostate volume and transitional zone volume were measured via transrectal ultrasound. Statistical analysis was performed by using Student's t-test.

    Results

    There were statistical differences between the two groups with respect to total cholesterol (p=0.045), triglycerides (p<0.001), HDL-C (p<0.001), glucose (p<0.001), blood pressure (p<0.001) and obesity (p<0.001), respectively. However, there was no significant difference on comparison of the total prostate volume and transitional zone volume, the maximal flow rate, the residual volume, IPSS, IIEF, PSA and LDL-C.

    Conclusions

    The results of this study suggest that BPH patients with metabolic syndrome X have higher total cholesterol, triglycerides, glucose, blood pressure and obesity, and lower HDL-C. Yet there was no significant difference in the voiding symptoms and erectile function between the patients with BPH who had or didn't have metabolic syndrome X.

    Keywords
    Benign prostatic hyperplasia; Metabolic syndrome X; Erectile dysfunction

    Tables

    Table 1
    Comparison of the biochemical factors in the patients with benign prostatic hyperplasia (BPH) and with or without metabolic syndrome

    Table 2
    Comparison of the voiding factors in the patients with BPH and with or without metabolic syndrome

    Table 3
    Comparison of sexual function in the patients with BPH and with or without metabolic syndrome

    References

      1. Kim JH, Shim BS, Hong YS. The relating factors of metabolic syndrome to benign prostatic hyperplasia. Korean J Urol 2005;46:1046–1050.
      1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
      1. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22:237–246.
      1. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;106:599–604.
      1. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology 1999;53:1–6.
      1. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29–36.
      1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.
      1. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori 2004;52:291–294.
      1. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptom and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001;2:297–301.
      1. Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology 1995;46(3) Suppl A:23–25.
      1. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001;56:702–708.
      1. Guay AT. Sexual dysfunction in the diabetic patient. Int J Impot Res 2001;13 Suppl 5:S47–S50.
      1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.
      1. Guirao Sanchez L, Garcia-Giralda Ruiz L, Sandoval Martinez C, Mocciaro Loveccio A. Erectile dysfunction in primary care as possible marker of health status: associated factors and response to sildenafil. Aten Primaria 2002;30:290–296.
      1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–2497.
      1. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.
      1. Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 1990;17:509–516.
      1. Nugent AP. The metabolic syndrome. BNF Nutr Bull 2004;29:36–43.
      1. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477–486.
      1. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725–1729.
      1. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trial. Diabetologia 2004;47:1914–1923.
      1. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081–1090.
      1. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989;32 Suppl:465A.
      1. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate cancer Prostatic Dis 1998;1:157–162.
      1. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003;10:569–574.
      1. Kim JH, Shim BS, Kim JS, Hong YS. Voiding dysfunction of men is associated metabolic syndrome. Korean J Urol 2006;47:257–262.
    Cited by
    Crossref 5
    Google Scholar 
    Scopus 4
    MeSH Terms
    Adult
    Blood Glucose
    Blood Pressure
    Cholesterol
    Consensus
    Diagnosis
    Education
    Erectile Dysfunction
    Humans
    Lipoproteins
    Male
    Metabolic Syndrome X*
    Obesity
    Prostate
    Prostate-Specific Antigen
    Prostatic Hyperplasia*
    Residual Volume
    Triglycerides
    Ultrasonography
    Metrics
    Share
    Tables
    slide
    slide
    slide

    1 / 3

    PERMALINK